Hosted on MSN11mon
Samsung Biologics inks US$352.7 mln deal with Belgium-based UCB
SEOUL, March 6 (Yonhap) -- Samsung Biologics Co. said Wednesday it has signed a US$352.7 million deal with Belgium-based biopharmaceutical firm UCB to manufacture the latter's products. The deal ...
PharmiWeb2h
BIMZELX[®] (bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)
UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®â–¼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...
Pharmaceutical Technology11d
Top 20 biopharma companies’ market caps rise 1.7% over 2024 amid policy
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...
pharmaphorum6d
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m
Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...
PharmiWeb12d
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...